Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD

1.845  -0.07 (-3.91%)

After market: 1.78 -0.06 (-3.52%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to THTX. THTX was compared to 571 industry peers in the Biotechnology industry. While THTX is still in line with the averages on profitability rating, there are concerns on its financial health. THTX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year THTX has reported negative net income.
THTX had a negative operating cash flow in the past year.
In the past 5 years THTX always reported negative net income.
THTX had a negative operating cash flow in each of the past 5 years.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -4.53%, THTX belongs to the top of the industry, outperforming 89.70% of the companies in the same industry.
THTX has a Return On Invested Capital of 46.63%. This is amongst the best in the industry. THTX outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA -4.53%
ROE N/A
ROIC 46.63%
ROA(3y)-36.02%
ROA(5y)-28.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600

1.3 Margins

With an excellent Operating Margin value of 11.77%, THTX belongs to the best of the industry, outperforming 95.20% of the companies in the same industry.
THTX has a Gross Margin of 76.97%. This is amongst the best in the industry. THTX outperforms 85.79% of its industry peers.
In the last couple of years the Gross Margin of THTX has grown nicely.
Industry RankSector Rank
OM 11.77%
PM (TTM) N/A
GM 76.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y1.53%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so THTX is creating value.
The number of shares outstanding for THTX has been increased compared to 1 year ago.
The number of shares outstanding for THTX has been reduced compared to 5 years ago.
The debt/assets ratio for THTX is higher compared to a year ago.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.89, we must say that THTX is in the distress zone and has some risk of bankruptcy.
THTX has a Altman-Z score of -5.89. This is in the lower half of the industry: THTX underperforms 65.90% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACC4.2
WACC11.1%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that THTX should not have too much problems paying its short term obligations.
THTX has a Current ratio of 1.08. This is amonst the worse of the industry: THTX underperforms 87.57% of its industry peers.
THTX has a Quick Ratio of 1.08. This is a bad value and indicates that THTX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.97, THTX is not doing good in the industry: 87.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 0.97
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

THTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.87%, which is quite impressive.
Looking at the last year, THTX shows a small growth in Revenue. The Revenue has grown by 5.75% in the last year.
The Revenue has been growing by 12.58% on average over the past years. This is quite good.
EPS 1Y (TTM)91.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)5.75%
Revenue growth 3Y7.37%
Revenue growth 5Y12.58%
Sales Q2Q%8.37%

3.2 Future

THTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.97% yearly.
The Revenue is expected to grow by 5.31% on average over the next years.
EPS Next Y103.61%
EPS Next 2Y44.2%
EPS Next 3Y29.68%
EPS Next 5Y17.97%
Revenue Next Year1.81%
Revenue Next 2Y2.14%
Revenue Next 3Y4.05%
Revenue Next 5Y5.31%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THTX. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 24.43, THTX is valued on the expensive side.
THTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. THTX is cheaper than 93.61% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of THTX to the average of the S&P500 Index (22.70), we can say THTX is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 24.43
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of THTX indicates a rather cheap valuation: THTX is cheaper than 98.40% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.13
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as THTX's earnings are expected to grow with 29.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.2%
EPS Next 3Y29.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

NASDAQ:THTX (2/21/2025, 8:00:01 PM)

After market: 1.78 -0.06 (-3.52%)

1.845

-0.07 (-3.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)04-08 2025-04-08/bmo
Inst Owners25.27%
Inst Owner Change-98.74%
Ins Owners0.91%
Ins Owner ChangeN/A
Market Cap84.83M
Analysts84
Price Target4.21 (128.18%)
Short Float %0.03%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)155.33%
Min EPS beat(2)94.17%
Max EPS beat(2)216.48%
EPS beat(4)4
Avg EPS beat(4)99.92%
Min EPS beat(4)20.75%
Max EPS beat(4)216.48%
EPS beat(8)5
Avg EPS beat(8)50.48%
EPS beat(12)6
Avg EPS beat(12)20.64%
EPS beat(16)8
Avg EPS beat(16)9.93%
Revenue beat(2)0
Avg Revenue beat(2)-5.02%
Min Revenue beat(2)-8.51%
Max Revenue beat(2)-1.53%
Revenue beat(4)0
Avg Revenue beat(4)-8.53%
Min Revenue beat(4)-21.53%
Max Revenue beat(4)-1.53%
Revenue beat(8)0
Avg Revenue beat(8)-8.48%
Revenue beat(12)0
Avg Revenue beat(12)-8.71%
Revenue beat(16)1
Avg Revenue beat(16)-9.81%
PT rev (1m)-2.41%
PT rev (3m)-29.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-4.77%
EPS NY rev (3m)-4.77%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.43
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 8.13
EPS(TTM)-0.1
EYN/A
EPS(NY)0.08
Fwd EY4.09%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS1.83
BVpS-0.43
TBVpS-0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.53%
ROE N/A
ROCE 59.02%
ROIC 46.63%
ROICexc N/A
ROICexgc N/A
OM 11.77%
PM (TTM) N/A
GM 76.97%
FCFM N/A
ROA(3y)-36.02%
ROA(5y)-28.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y1.53%
F-Score4
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 2.86
Cap/Depr 105.49%
Cap/Sales 3.56%
Interest Coverage 1.04
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 0.97
Altman-Z -5.89
F-Score4
WACC11.1%
ROIC/WACC4.2
Cap/Depr(3y)21.55%
Cap/Depr(5y)22.65%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y103.61%
EPS Next 2Y44.2%
EPS Next 3Y29.68%
EPS Next 5Y17.97%
Revenue 1Y (TTM)5.75%
Revenue growth 3Y7.37%
Revenue growth 5Y12.58%
Sales Q2Q%8.37%
Revenue Next Year1.81%
Revenue Next 2Y2.14%
Revenue Next 3Y4.05%
Revenue Next 5Y5.31%
EBIT growth 1Y152.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.61%
EBIT Next 3Y51.82%
EBIT Next 5Y35.88%
FCF growth 1Y64.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.34%
OCF growth 3YN/A
OCF growth 5YN/A